Panalgo, a Norstella company dedicated to revolutionizing
healthcare data analytics, is announcing a new venture with partner
OM1, a forefront leader in real-world evidence (RWE) insights
generation, deep specialty data, and advanced AI healthcare
technologies. This latest offering enables Panalgo to host OM1's
PremiOM enriched deep clinical datasets across multiple therapeutic
areas and chronic conditions in the IHD Analytics platform.
BOSTON, June 19,
2024 /PRNewswire-PRWeb/ -- Panalgo, a Norstella
company dedicated to revolutionizing healthcare data analytics, is
announcing a new venture with partner OM1, a forefront leader in
real-world evidence (RWE) insights generation, deep specialty data,
and advanced AI healthcare technologies. This latest offering
enables Panalgo to host OM1's PremiOM enriched deep clinical
datasets across multiple therapeutic areas and chronic conditions
in the IHD Analytics platform.
"We are thrilled to expand our partnership
with OM1 and welcome them into our Partner Network. OM1 shares our
goals in accelerating RWE generation by breaking barriers in the
traditional ways clients access data," said Erik Maul, Senior Director of Partnerships at
Panalgo.
The announcement coincides with Panalgo's and OM1's
participation in the DIA 2024 Global Annual Meeting in San Diego, where industry regulators,
governments, academics, innovators, and patients will address
challenges facing the life sciences community.
The Panalgo and OM1 partnership bundles OM1's robust suite of
autoimmune, dermatologic, neuroscience, and other chronic condition
datasets with Panalgo's industry-leading Instant Health Data
Analytics (IHD) platform so healthcare stakeholders can more easily
achieve their research objectives with access to deep clinical data
sets for a multitude of various chronic conditions. OM1's PremiOM
datasets, enriched with clinical endpoints and outcomes, provide
research-ready, regulatory-grade insights to accelerate research
and improve decision-making.
"We are excited to work with Panalgo as a strategic partner to
provide customers with access to deep multi-source longitudinal
data that drives better patient outcomes at an accelerated pace,"
said Shawn Bates, Chief Commercial
Officer, OM1. "Together, we look forward to transforming real-world
data into actionable intelligence to advance patient research and
improve standard of care."
OM1 offers the largest linked longitudinal condition datasets
with deep clinical and outcomes data. Datasets include conditions
in rheumatology/immunology, respiratory/otolaryngology,
dermatology, gastroenterology, mental health/neuroscience, and
cardiometabolic therapeutic areas. The readily available
productized datasets for licensing and/or research analytics are
highly curated, drawn from specialty networks with pre-defined
populations, and enriched through endpoint amplification using AI
and unstructured clinical data.
Panalgo's IHD Analytics is the industry-leading self-service,
enterprise RWE analytical platform enabling rapid analytics and
insights. With no complex programming required, it's 85% faster
than traditional custom programming, with a unique,
healthcare-specific data model and extensive library of
customizable algorithms, plus integrated machine learning and
automated documentation. IHD answers questions in real time by
conducting risk evaluations, assessing access to treatment,
exploring the impact of regulatory action, and evaluating emergent
safety issues. It enables clients to generate evidence for the
effectiveness, safety, and value of your treatments more fully.
"We are thrilled to expand our partnership with OM1 and welcome
them into our Partner Network. OM1 shares our goals in accelerating
RWE generation by breaking barriers in the traditional ways clients
access data," said Erik Maul, Senior
Director of Partnerships at Panalgo. "With OM1's specialized data
loaded and ready to go in the IHD Analytics platform, clients can
worry less about procurement and setup and get right to their
analysis, compounding the value and accelerating the time to
meaningful research."
About OM1:
OM1 is pioneering cutting-edge healthcare innovation through its
insights-driven technology and data. It specializes in personalized
medicine, evidence generation, and real-world evidence (RWE)
research powered by next-generation AI platforms, regulatory-grade
deep longitudinal data, and globally recognized thought leadership.
OM1 is led by a diverse group of scientists, engineers,
researchers, and clinicians with over 30 years of experience in
RWD/RWE who have written the handbook on building clinical
registries and developing the outcomes measure framework. OM1's
unprecedented innovation takes RWE from bench to practice,
delivering unparalleled personalized impact on the outcomes of
patients and the advancement of research. For more information,
visit OM1.com.
About Panalgo:
Panalgo, a Norstella company, is your partner on the healthcare
data analytics journey. Our Instant Health Data (IHD) platform
eliminates complex programming, making data analysis faster and
decision-making more impactful. Through partnerships across the
industry, we streamline access to real-world data, offering a
complete solution from data to insights. Whether it's
industry-leading software, access to data, expert analytic
services, or any combination of the three, we're here to support
you at any stage of your analytics journey. For more information,
visit Panalgo.com and follow us on LinkedIn.
If you're interested in learning more about how you can leverage
OM1 data in Panalgo's IHD platform, get in touch today.
To learn more about OM1's real-world data and patented AI
technology, please email info@om1.com.
For media inquiries:
Christine Birkner
cbirkner@mmitnetwork.com
Media Contact
Christine Birkner, Panalgo, 1
781-290-0808,
cbirkner@mmitnetwork.com, www.panalgo.com
View original
content:https://www.prweb.com/releases/panalgo-and-om1-expand-partnership-to-offer-om1s-premiom-datasets-in-panalgos-ihd-analytics-platform-302176499.html
SOURCE Panalgo